Herceptin: mechanisms of action and resistance
Tóm tắt
Từ khóa
Tài liệu tham khảo
Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106
Slamon, 1989, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, 244, 707, 10.1126/science.2470152
Hudziak, 1987, Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells, Proc. Natl Acad. Sci. USA, 84, 7159, 10.1073/pnas.84.20.7159
Bouchard, 1989, Stochastic appearance of mammary tumors in transgenic mice carrying the mmtv/c-neu oncogene, Cell, 57, 931, 10.1016/0092-8674(89)90331-0
Guy, 1992, Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease, Proc. Natl Acad. Sci. USA, 89, 10578, 10.1073/pnas.89.22.10578
Guy, 1996, Activated neu induces rapid tumor progression, J. Biol. Chem., 271, 7673, 10.1074/jbc.271.13.7673
Depowski, 2002, Comparative analysis of Her-2/neu protein overexpression in breast cancer using paraffin-embedded tissue and cytologic specimens, Mod. Pathol., 15, 70A
Joensuu, 2003, Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study, Clin. Cancer Res., 9, 923
Leonard, 2002, Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer, Br. J. Surg., 89, 262, 10.1046/j.0007-1323.2001.02022.x
Press, 1997, HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas, J. Clin. Oncol., 15, 2894, 10.1200/JCO.1997.15.8.2894
Press, 2002, Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens, J. Clin. Oncol., 20, 3095, 10.1200/JCO.2002.09.094
Muss, 1994, c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer, New Engl. J. Med., 330, 1260, 10.1056/NEJM199405053301802
Paik, 1998, erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer, J. Natl Cancer Inst., 90, 1361, 10.1093/jnci/90.18.1361
Thor, 1998, erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer, J. Natl. Cancer Inst., 90, 1346, 10.1093/jnci/90.18.1346
Eceles, 2001, The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis, J. Mamm. Gland Biol. Neoplasia, 6, 393, 10.1023/A:1014730829872
Paik, 1990, Pathologic findings from the national surgical adjuvant breast and bowel project: prognostic significance of erbB-2 protein overexpression in primary breast cancer, J. Clin. Oncol., 8, 103, 10.1200/JCO.1990.8.1.103
Niehans, 1993, Stability of HER-2/neu expression over time and at multiple metastatic sites, J. Natl Cancer Inst., 85, 1230, 10.1093/jnci/85.15.1230
Carter, 1992, Humanization of an anti-p185her2 antibody for human cancer therapy, Proc. Natl Acad. Sci. USA, 89, 4285, 10.1073/pnas.89.10.4285
Baselga, 2001, Mechanism of action of trastuzumab and scientific update, Semin. Oncol., 28, 4, 10.1016/S0093-7754(01)90276-3
Sliwkowski, 1999, Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin), Semin. Oncol., 26, 60
Le, 2003, The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition, J. Biol. Chem., 278, 23441, 10.1074/jbc.M300848200
Nahta, 2004, P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells, Cancer Res., 64, 3981, 10.1158/0008-5472.CAN-03-3900
Nahta, 2004, The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells, Cancer Res., 64, 2343, 10.1158/0008-5472.CAN-03-3856
Nagata, 2004, PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients, Cancer Cell, 6, 117, 10.1016/j.ccr.2004.06.022
Lane, 2000, ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency, Mol. Cell Biol., 20, 3210, 10.1128/MCB.20.9.3210-3223.2000
Lane, 2001, Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling, Ann. Oncol., 12, 21, 10.1023/A:1011155606333
Chang, 2003, Induction of apoptosis without change in cell proliferation in primary breast cancers with neoadjuvant trastuzumab, Breast Cancer Res. Treat., 82, 24
Gennari, 2004, Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2, Clin. Cancer Res., 10, 5650, 10.1158/1078-0432.CCR-04-0225
Laughner, 2001, HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1 alpha (HIF-1 alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression, Mol. Cell Biol., 21, 3995, 10.1128/MCB.21.12.3995-4004.2001
Yen, 2000, Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis, Oncogene, 19, 3460, 10.1038/sj.onc.1203685
Izumi, 2002, Tumour biology: Herceptin acts as an anti-angiogenic cocktail, Nature, 416, 279, 10.1038/416279b
Klos, 2003, Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone, Cancer, 98, 1377, 10.1002/cncr.11656
Petit, 1997, Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors, Am. J. Pathol., 151, 1523
Cooley, 1999, Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu, Exp. Hematol., 27, 1533, 10.1016/S0301-472X(99)00089-2
Lewis, 1993, Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies, Cancer Immunol. Immunother., 37, 255, 10.1007/BF01518520
Clynes, 2000, Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets, Nat. Med., 6, 443, 10.1038/74704
Repka, 2003, Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study, Clin. Cancer Res., 9, 2440
Lin, 1991, A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells, Oncogene, 6, 639
Pupa, 1993, The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage, Oncogene, 8, 2917
Zabrecky, 1991, The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, sk-br-3, J. Biol. Chem., 266, 1716, 10.1016/S0021-9258(18)52354-1
Christianson, 1998, NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer, Cancer Res., 58, 5123
Colomer, 2000, Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer, Clin. Cancer Res., 6, 2356
Leitzel, 1995, Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer, J. Clin. Oncol., 13, 1129, 10.1200/JCO.1995.13.5.1129
Yamauchi, 1996, Elevated circulating HER-2/neu-related protein (NRP) is associated with low response rate (RR) to first-line hormone therapy (HT) in patients with estrogen and/or progesterone receptor positive (ER, PR Pos) advanced breast cancer (AdBrCA) (Meeting abstract), Proc. Am. Soc. Clin. Oncol., 15, A116
Molina, 2002, NH2-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer, Clin. Cancer Res., 8, 347
Molina, 2001, Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells, Cancer Res., 61, 4744
Esteva, 2004, Clinical utility of circulating HER-2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients undergoing trastuzumab-based therapy, Breast Can. Res. Treat., 88, 6001
Esteva, 2002, Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer, J. Clin. Oncol., 20, 1800, 10.1200/JCO.2002.07.058
Pegram, 1999, Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers, Oncogene, 18, 2241, 10.1038/sj.onc.1202526
Pegram, 2004, Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer, J. Natl Cancer Inst., 96, 739, 10.1093/jnci/djh131
Pietras, 1994, Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells, Oncogene, 9, 1829
Pietras, 1998, Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs, Oncogene, 17, 2235, 10.1038/sj.onc.1202132
Pietras, 1999, Monoclonal antibody to HER-2/neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene, Cancer Res., 59, 1347
Mayfield, 2001, DNA strand breaks and cell cycle perturbation in Herceptin treated breast cancer cell lines, Breast Cancer Res. Treat., 70, 123, 10.1023/A:1012999012192
Kauraniemi, 2004, Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines, Oncogene, 23, 1010, 10.1038/sj.onc.1207200
Bast, 2001, 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American society of clinical oncology, J. Clin. Oncol., 19, 1865, 10.1200/JCO.2001.19.6.1865
Bilous, 2002, Predicting HER2 status of breast cancer from basic pathology features: HER2 status of 1500 breast cancers determined by immunohistochemistry and fluorescence in situ hybridisation with pathology correlation, Eur. J. Cancer, 38, S52, 10.1016/S0959-8049(02)80138-1
Fornier, 2002, HER2 testing and correlation with efficacy of trastuzumab therapy, Oncology (Huntingt.), 16, 1340
Pauletti, 2000, Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry, J. Clin. Oncol., 18, 3651, 10.1200/JCO.2000.18.21.3651
Seidman, 2001, Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification, J. Clin. Oncol., 19, 2587, 10.1200/JCO.2001.19.10.2587
Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, New Engl. J. Med., 344, 783, 10.1056/NEJM200103153441101
Vogel, 2002, Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer, J. Clin. Oncol., 20, 719, 10.1200/JCO.20.3.719
Persons, 2000, Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study, Ann. Clin. Lab. Sci., 30, 41
Mass, 2001, Improved survival benefit from Herceptin (tumour biology: Herceptin acts as an anti-angiogenic cocktail trastuzumab) in patients selected by fluorescence in situ hybridization (FISH), Proc. Am. Soc. Clin. Oncol., 20, 85
Harris, 2001, Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy, J. Clin. Oncol., 19, 1698, 10.1200/JCO.2001.19.6.1698
Jacobs, 1999, Specificity of HercepTest in determining HER-2/neu status of breast cancers using the united states food and drug administration-approved scoring system, J. Clin. Oncol., 17, 1983, 10.1200/JCO.1999.17.7.1983
Esteva, 2003, Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients—M.D. Anderson clinical validation study, Breast Cancer Res. Treat., 82, A17
Kostler, 2004, Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer, Clin. Cancer Res., 10, 1618, 10.1158/1078-0432.CCR-0385-3
Baselga, 2001, Phase I and II clinical trials of trastuzumab, Ann. Oncol., 12, 49, 10.1023/A:1011167909059
Baselga, 1996, Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer, J. Clin. Oncol., 14, 737, 10.1200/JCO.1996.14.3.737
Cobleigh, 1999, Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER-2 overexpressing metastatic breast cancer that has progresssed after chemotherapy for metastatic disease, J. Clin. Oncol., 17, 2639, 10.1200/JCO.1999.17.9.2639
Seidman, 2002, Cardiac dysfunction in the trastuzumab clinical trials experience, J. Clin. Oncol., 20, 1215, 10.1200/JCO.20.5.1215
Ozcelik, 2002, Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy, Proc. Natl Acad. Sci. USA., 99, 8880, 10.1073/pnas.122249299
Winer, 2001, New combinations with Herceptin((R)) in metastatic breast cancer, Oncology, 61, 50, 10.1159/000055402
Pegram, 1998, Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment, J. Clin. Oncol., 16, 2659, 10.1200/JCO.1998.16.8.2659
Burstein, 2001, Clinical activity of trastuzumab and vinorelbine in women with HER-2 overexpressing metastatic breast cancer, J. Clin. Oncol., 19, 2722, 10.1200/JCO.2001.19.10.2722
O'Shaughnessy, 2001, Gemcitabine and trastuzamab for HER-2 positive metastatic breast cancer: preliminary results of a phase II study, Breast Cancer Res. Treat., 69, 302
Konecny, 2001, HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer, Breast Cancer Res. Treat., 69, 53, 10.1023/A:1012226006395
Pegram, 2000, Trastuzumab and chemotherapeutics: drug interactions and synergies, Semin. Oncol., 27, 21
Nabholtz, 2000, Preliminary results of two open-label multicenter pilot phase II trials with Herceptin in combination with docetaxel and platinum salts (cis- or carboplatin) (TCH) as therapy for advanced breast cancer in women with overexpresing HER2/neu, Breast Cancer Res. Treat., 58, 327
Robert, 2002, Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER2/Neu positive advanced breast cancer, Breast Cancer Res. Treat., 76, 35
Slamon, 2001, Phase II pilot study of Herceptin combined with taxotere and carboplatin in metastatic breast cancer patients overexpressing the HER2-neu proto-oncogene: a pilot study of the UCLA network, Proc. Am. Soc. Clin. Oncol., 20, 193
Paik, 2002, Real-world performance of HER2 testing - national surgical adjuvant breast and bowel project experience, J. Natl Cancer Inst., 94, 852, 10.1093/jnci/94.11.852
Roche, 2002, Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831, J. Natl Cancer Inst., 94, 855, 10.1093/jnci/94.11.855
Burstein, 2003, Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study, J. Clin. Oncol., 21, 46, 10.1200/JCO.2003.03.124
Buzdar, 2004, Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease, J. Clin. Oncol., 22, 520, 10.1200/jco.2004.22.14_suppl.520
Paez, 2004, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, 304, 1497, 10.1126/science.1099314
Stephens, 2004, Lung cancer: intragenic ERBB2 kinase mutations in tumours, Nature, 431, 525, 10.1038/431525b
Burstein, 2003, Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm, J. Clin. Oncol., 21, 2889, 10.1200/JCO.2003.02.018
Graus-Porta, 1997, ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling, Eur. Med. Biol. Org. J., 16, 1647, 10.1093/emboj/16.7.1647
Bacus, 2004, Differences in response of breast cancer molecular profiles of patients likely to respond to either tyrosine kinase inhibitors or to erbB targeted therapies, J. Clin. Oncol., 22, 3097, 10.1200/jco.2004.22.14_suppl.3097
Yakes, 2002, Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action, Cancer Res., 62, 4132
Kute, 2004, Development of Herceptin resistance in breast cancer cells, Cytometry, 57A, 86, 10.1002/cyto.a.10095
Yee, 2002, The insulin-like growth factor system as a treatment target in breast cancer, Semin. Oncol., 29, 86, 10.1053/sonc.2002.34060
Lu, 2001, Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin), J. Natl Cancer Inst., 93, 1852, 10.1093/jnci/93.24.1852
Nahta, 2003, HER-2-targeted therapy: lessons learned and future directions, Clin. Cancer Res., 9, 5078
Moulder, 2001, Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo, Cancer Res., 61, 8887
Arpino, 2004, Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition, Breast Cancer Res. Treat., 88, 23
Kelland, 2001, Preclinical antitumor activity and pharmacodynamic studies with the farnesylprotein transferase inhibitor R115777 in human breast cancer, Clin. Cancer Res., 7, 3544
Nahta, 2002, Rate-limiting effects of cyclin D1 in transformation by ErbB2 predicts synergy between Herceptin and flavopiridol, Cancer Res., 62, 2267
Nahta, 2003, Growth factor receptors in breast cancer: potential for therapeutic intervention, Oncologist, 8, 5, 10.1634/theoncologist.8-1-5
Wu, 2002, Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways, Mol. Cancer Ther., 1, 695
Hidalgo, 2000, The rapamycin-sensitive signal transduction pathway as a target for cancer therapy, Oncogene, 19, 6680, 10.1038/sj.onc.1204091
Chan, 2002, First report: a phase 2 study of the safety and activity of CCI-779 for patients with locally advanced or metastatic breast cancer failing prior chemotherapy, Proc. Am. Soc. Clin. Oncol., 175
Esteva, 2004, Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer, The Oncologist, 9, 4, 10.1634/theoncologist.9-suppl_3-4
Agus, 2002, Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth, Cancer Cell, 2, 127, 10.1016/S1535-6108(02)00097-1
Cho, 2003, Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab, Nature, 421, 756, 10.1038/nature01392
Batra, 1992, Recombinant anti-erbB-2 immunotoxins containing pseudomonas exotoxin, Proc. Natl Acad. Sci. USA, 89, 5867, 10.1073/pnas.89.13.5867
Rosenblum, 1999, Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models, Clin. Cancer Res., 5, 865
Rosenblum, 2000, A novel recombinant fusion toxin targeting HER-2/NEU-over-expressing cells and containing human tumor necrosis factor, Int. J. Cancer, 88, 267, 10.1002/1097-0215(20001015)88:2<267::AID-IJC19>3.0.CO;2-G
Wels, 1992, Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor, Cancer Res., 52, 6310
King, 1996, The performance of e23(Fv)PE, recombinant toxins targeting the erbB-2 protein, Semin. Cancer Biol., 7, 79, 10.1006/scbi.1996.0012
Reiter, 1994, Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated pseudomonas exotoxin, Int. J. Cancer, 58, 142, 10.1002/ijc.2910580123
Rusnak, 2001, The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer, Cancer Res., 61, 7196
Allen, 2002, Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer, Semin. Oncol., 29, 11, 10.1053/sonc.2002.34049
Xia, 2002, Anti-tumor activity of GW57: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways, Oncogene, 21, 6255, 10.1038/sj.onc.1205794
Blackwell, 2004, Determining molecular phenotypes of metastatic breast cancer that respond to the small molecule inhibitor of ErbB1 and ErbB2, lapatinib (GW572016), Breast Cancer Res. Treat., 88, 302
Yu, 1990, Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products, Proc. Natl Acad. Sci. USA, 87, 4499, 10.1073/pnas.87.12.4499
Yu, 1995, Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu, Oncogene, 11, 1383
Hortobagyi, 2001, Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial, J. Clin. Oncol., 19, 3422, 10.1200/JCO.2001.19.14.3422
Weiner, 1993, A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16, Cancer Res., 53, 94
Shalaby, 1995, Bispecific HER2 x CD3 antibodies enhance T-cell cytotoxicity in vitro and localize to HER2-overexpressing xenografts in nude mice, Clin. Immunol. Immunopathol., 74, 185, 10.1006/clin.1995.1027
Weiner, 1995, Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII, Cancer Res., 55, 4586
Weiner, 1995, Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII, J. Hematother., 4, 453, 10.1089/scd.1.1995.4.453
Knutson, 2002, Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity, Clin. Cancer Res., 8, 1014
Bernhard, 2002, Vaccination against HER-2/neu oncogenic protein, Endocr. Relat. Cancer, 9, 33, 10.1677/erc.0.0090033